DERINIK 0.18 Milligram Tablets Ireland - English - HPRA (Health Products Regulatory Authority)

derinik 0.18 milligram tablets

actavis group ptc ehf - pramipexole dihydrochloride monohydrate - tablets - 0.18 milligram

DERINIK 0.7 Milligram Tablets Ireland - English - HPRA (Health Products Regulatory Authority)

derinik 0.7 milligram tablets

actavis group ptc ehf - pramipexole dihydrochloride monohydrate - tablets - 0.7 milligram

DERINIK 0.088 Milligram Tablets Ireland - English - HPRA (Health Products Regulatory Authority)

derinik 0.088 milligram tablets

actavis group ptc ehf - pramipexole dihydrochloride monohydrate - tablets - 0.088 milligram

DERINIK Tablets 0.088 Milligram Ireland - English - HPRA (Health Products Regulatory Authority)

derinik tablets 0.088 milligram

actavis group ptc ehf - pramipexole dihydrochloride monohydrate - tablets - 0.088 milligram

DERINIK Tablets 0.18 Milligram Ireland - English - HPRA (Health Products Regulatory Authority)

derinik tablets 0.18 milligram

actavis group ptc ehf - pramipexole dihydrochloride monohydrate - tablets - 0.18 milligram

DERINIK Tablets 0.7 Milligram Ireland - English - HPRA (Health Products Regulatory Authority)

derinik tablets 0.7 milligram

actavis group ptc ehf - pramipexole dihydrochloride monohydrate - tablets - 0.7 milligram

Pemetrexed 25mg/ml Concentrate for Solution for Infusion (Caduceus Pharma Ltd) United Kingdom - English - myHealthbox

pemetrexed 25mg/ml concentrate for solution for infusion (caduceus pharma ltd)

caduceus pharma ltd. - pemetrexed - concentrate for solution for infusion - 25mg - folic acid analogues - malignant pleural mesothelioma pemetrexed in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancer pemetrexed in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology pemetrexed is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy

COSOPT Preservative-Free 20 mg/ml + 5 mg/ml eye drops, solution United Kingdom - English - myHealthbox

cosopt preservative-free 20 mg/ml + 5 mg/ml eye drops, solution

santen oy - dorzolamide hydrochloride - eye drops, solution, single dose container - 22.26 mg - antiglaucoma preparations and miotics, beta blocking agents, timolol, combinations - indicated in the treatment of elevated intraocular pressure (iop) in patients with open-angle glaucoma or pseudoexfoliative glaucoma when topical beta-blocker monotherapy is not sufficient.

Ropilynz XL 2 mg prolonged-release tablets United Kingdom - English - myHealthbox

ropilynz xl 2 mg prolonged-release tablets

lupin (europe) limited - ropinirole - prolonged-release tablet - 2 mg - dopamine agonists - treatment of parkinson's disease under the following conditions: initial treatment as monotherapy, in order to delay the introduction of levodopa in combination with levodopa, over the course of the disease, when the effect of levodopa wears off or becomes inconsistent and fluctuations in the therapeutic effect occur (“end of dose” or “on-off” type fluctuations).

Ropilynz XL 4 mg prolonged-release tablets United Kingdom - English - myHealthbox

ropilynz xl 4 mg prolonged-release tablets

lupin (europe) limited - ropinirole - prolonged-release tablet - 4mg - dopamine agonists - treatment of parkinson's disease under the following conditions: initial treatment as monotherapy, in order to delay the introduction of levodopa in combination with levodopa, over the course of the disease, when the effect of levodopa wears off or becomes inconsistent and fluctuations in the therapeutic effect occur (“end of dose” or “on-off” type fluctuations).